Skip to main content
SVRASavara, Inc.Sell5.1·$4.48
SellModerate Confidence
Investment thesis

Savara is a pre-revenue biotechnology company in a golden cross breakout with 78% analyst price target upside, but quality scores only 1.6 out of 10 with fully negative free cash flow and a put/call ratio of 28.33 — the highest in this group — signaling extreme options market bearishness despite the bullish technical setup.

Thesis pillars

  • Extreme Put Call Bearish Signal↑Improving
  • Bullish Breakout Technical Setup↓Deteriorating
  • Quality Below Floor Cash Burn↑Improving
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Mar 13, 2026· older than 90 days

Full reasoning →

Open full analysis

Savara, Inc. (SVRA) Stock Analysis

Falling Knife setup · Inst Constrain edge

SellVALUE-TRAP 2/5ShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $4.48: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum.

Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole product candidate, for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no FDA-approved treatments. The company has no approved products or... Read more

$4.48+114.7% A.UpsideScore 5.1/10#130 of 240 Biotechnology
QualityF-score4 / 9FCF yield-7.45%
Stop $4.17Analyst target $9.62(−13% haircut)A.R:R 8.4:1
Analyst consensus$11.06+146.8%9 analysts with price targets
$9.62Analyst target
$4.48price
$11.06mean
$16

Sell if holding. Engine safety override at $4.48: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Score 5.1/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 114d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 16, 2026

Recent Developments — Savara, Inc.

Latest item Nov 16, 2026 · Generated 2026-11-18T12:02:26Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Fri, Mar 12, 2027114d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.8 < 4.0)
Value-trap signals (2/5): Margin compression (op margin -9.6%), Material insider selling (14 sells, 0.13% of cap)

Key Metrics

P/E (TTM)—
P/E (Fwd)-12.1
Mkt Cap$988M
EV/EBITDA-7.1
Profit Mgn0.0%
ROE-151.0%
Rev Growth—
Beta0.30
DividendNone
Analysts with ratings15

Quality Signals

Piotroski F4/9

Options Flow

P/C0.69bullish

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Rsi
3.5
Macd
3.7
Volume
5.3
Volume distribution (falling OBV)Below 200-MA, MA slope -3.3%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.0
Value Rank
5.0
Growth Rank
5.0

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
News Activity
6.0
Earnings concerns: 0B/2M
GatesMomentum 2.9<4.5Death cross (50MA < 200MA)A.R:R 8.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 114d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
37 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $4.13Resistance $5.21

Price Targets

$4
$10
A.Upside+114.7%
A.R:R8.4:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (1.8 < 4.0)
! Value-trap signals (2/5): Margin compression (op margin -9.6%), Material insider selling (14 sells, 0.13% of cap)
! momentum at 2.9 (below the engine's 4.5 threshold)

Earnings

M
M
M
M
0/4 beats
Next Earnings2027-03-12 (114d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SVRA stock a buy right now?

Sell if holding. Engine safety override at $4.48: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 8.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Prior stop was $4.17. Score 5.1/10, moderate confidence.

What is the SVRA stock price target?

Analyst target: $9.62 (+114.7% upside). Prior stop was $4.17. Stop-loss: $4.17.

What are the risks of investing in SVRA?

Quality below floor (1.8 < 4.0); Value-trap signals (2/5): Margin compression (op margin -9.6%), Material insider selling (14 sells, 0.13% of cap).

Is SVRA overvalued or undervalued?

Savara, Inc. trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about SVRA?

15 analysts rate SVRA, with a consensus score of 4.3/5. 9 analysts publish price targets averaging $11.

What does Savara, Inc. do?Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole...

Savara is a clinical-stage biopharmaceutical company developing MOLBREEVI, an inhaled GM-CSF biologic and its sole product candidate, for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no FDA-approved treatments. The company has no approved products or commercial revenue; the FDA formally filed Savara's resubmitted Biologics License Application for MOLBREEVI in February 2026 and granted Priority Review. Savara outsources manufacturing to third-party partners including Fujifilm for drug substance and PARI for its proprietary nebulizer delivery device.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · MGTX (MeiraGTx Holdings plc) · HRMY (Harmony Biosciences Holdings, I) · CORT (Corcept Therapeutics Incorporat)
Home › Stocks › SVRA

Latest news

Latest News

Benzinga2d ago
Fiscal.ai5d ago
Fiscal.ai6d ago
Benzinga6d agoAnalyst
Fiscal.ai28d agoFda Decision
Benzinga28d ago
Benzinga42d ago
Benzinga42d ago
Benzinga86d agoProduct
Benzinga99d agoFda Decision
Benzinga99d ago
Benzinga111d agoProduct
Benzinga163d agoLeadership Change